Detection of circulating tumor DNA in patients with osteosarcoma

David M. Barris, Shoshana B. Weiner, Robert A. Dubin, Michael Fremed, Xusheng Zhang, Sajida Piperdi, Wendong Zhang, Shahina B. Maqbool, Jonathan Gill, Michael Roth, Bang H. Hoang, David S. Geller, Richard Gorlick, Daniel A. Weiser

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Identification and quantification of somatic alterations in plasma-derived, circulating tumor DNA (ctDNA) is gaining traction as a non-invasive and cost effective method of disease monitoring in cancer patients, particularly to evaluate response to treatment and monitor for disease recurrence. To our knowledge, genetic analysis of ctDNA in osteosarcoma has not yet been studied. To determine whether somatic alterations can be detected in ctDNA and perhaps applied to patient management in this disease, we collected germline, tumor, and serial plasma samples from pediatric, adolescent, and young adult patients with osteosarcoma and used targeted Next Generation Sequencing (NGS) to identify somatic single nucleotide variants (SNV), insertions and deletions (INDELS), and structural variants (SV) in 7 genes commonly mutated in osteosarcoma. We demonstrate that patient-specific somatic alterations identified through comparison of tumor-germline pairs can be detected and quantified in cell-free DNA of osteosarcoma patients.

Original languageEnglish (US)
Pages (from-to)12695-12704
Number of pages10
JournalOncotarget
Volume9
Issue number16
DOIs
StatePublished - Jan 1 2018

Fingerprint

Osteosarcoma
DNA
Neoplasms
Traction
Disease Management
Young Adult
Nucleotides
Pediatrics
Costs and Cost Analysis
Recurrence
Genes

Keywords

  • Circulating tumor DNA
  • Next Generation Sequencing
  • Osteosarcoma
  • Targeted sequencing
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Detection of circulating tumor DNA in patients with osteosarcoma. / Barris, David M.; Weiner, Shoshana B.; Dubin, Robert A.; Fremed, Michael; Zhang, Xusheng; Piperdi, Sajida; Zhang, Wendong; Maqbool, Shahina B.; Gill, Jonathan; Roth, Michael; Hoang, Bang H.; Geller, David S.; Gorlick, Richard; Weiser, Daniel A.

In: Oncotarget, Vol. 9, No. 16, 01.01.2018, p. 12695-12704.

Research output: Contribution to journalArticle

Barris, DM, Weiner, SB, Dubin, RA, Fremed, M, Zhang, X, Piperdi, S, Zhang, W, Maqbool, SB, Gill, J, Roth, M, Hoang, BH, Geller, DS, Gorlick, R & Weiser, DA 2018, 'Detection of circulating tumor DNA in patients with osteosarcoma', Oncotarget, vol. 9, no. 16, pp. 12695-12704. https://doi.org/10.18632/oncotarget.24268
Barris DM, Weiner SB, Dubin RA, Fremed M, Zhang X, Piperdi S et al. Detection of circulating tumor DNA in patients with osteosarcoma. Oncotarget. 2018 Jan 1;9(16):12695-12704. https://doi.org/10.18632/oncotarget.24268
Barris, David M. ; Weiner, Shoshana B. ; Dubin, Robert A. ; Fremed, Michael ; Zhang, Xusheng ; Piperdi, Sajida ; Zhang, Wendong ; Maqbool, Shahina B. ; Gill, Jonathan ; Roth, Michael ; Hoang, Bang H. ; Geller, David S. ; Gorlick, Richard ; Weiser, Daniel A. / Detection of circulating tumor DNA in patients with osteosarcoma. In: Oncotarget. 2018 ; Vol. 9, No. 16. pp. 12695-12704.
@article{459010e307f340a2a3c2b7c973cbb928,
title = "Detection of circulating tumor DNA in patients with osteosarcoma",
abstract = "Identification and quantification of somatic alterations in plasma-derived, circulating tumor DNA (ctDNA) is gaining traction as a non-invasive and cost effective method of disease monitoring in cancer patients, particularly to evaluate response to treatment and monitor for disease recurrence. To our knowledge, genetic analysis of ctDNA in osteosarcoma has not yet been studied. To determine whether somatic alterations can be detected in ctDNA and perhaps applied to patient management in this disease, we collected germline, tumor, and serial plasma samples from pediatric, adolescent, and young adult patients with osteosarcoma and used targeted Next Generation Sequencing (NGS) to identify somatic single nucleotide variants (SNV), insertions and deletions (INDELS), and structural variants (SV) in 7 genes commonly mutated in osteosarcoma. We demonstrate that patient-specific somatic alterations identified through comparison of tumor-germline pairs can be detected and quantified in cell-free DNA of osteosarcoma patients.",
keywords = "Circulating tumor DNA, Next Generation Sequencing, Osteosarcoma, Targeted sequencing, Targeted therapy",
author = "Barris, {David M.} and Weiner, {Shoshana B.} and Dubin, {Robert A.} and Michael Fremed and Xusheng Zhang and Sajida Piperdi and Wendong Zhang and Maqbool, {Shahina B.} and Jonathan Gill and Michael Roth and Hoang, {Bang H.} and Geller, {David S.} and Richard Gorlick and Weiser, {Daniel A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.24268",
language = "English (US)",
volume = "9",
pages = "12695--12704",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "16",

}

TY - JOUR

T1 - Detection of circulating tumor DNA in patients with osteosarcoma

AU - Barris, David M.

AU - Weiner, Shoshana B.

AU - Dubin, Robert A.

AU - Fremed, Michael

AU - Zhang, Xusheng

AU - Piperdi, Sajida

AU - Zhang, Wendong

AU - Maqbool, Shahina B.

AU - Gill, Jonathan

AU - Roth, Michael

AU - Hoang, Bang H.

AU - Geller, David S.

AU - Gorlick, Richard

AU - Weiser, Daniel A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Identification and quantification of somatic alterations in plasma-derived, circulating tumor DNA (ctDNA) is gaining traction as a non-invasive and cost effective method of disease monitoring in cancer patients, particularly to evaluate response to treatment and monitor for disease recurrence. To our knowledge, genetic analysis of ctDNA in osteosarcoma has not yet been studied. To determine whether somatic alterations can be detected in ctDNA and perhaps applied to patient management in this disease, we collected germline, tumor, and serial plasma samples from pediatric, adolescent, and young adult patients with osteosarcoma and used targeted Next Generation Sequencing (NGS) to identify somatic single nucleotide variants (SNV), insertions and deletions (INDELS), and structural variants (SV) in 7 genes commonly mutated in osteosarcoma. We demonstrate that patient-specific somatic alterations identified through comparison of tumor-germline pairs can be detected and quantified in cell-free DNA of osteosarcoma patients.

AB - Identification and quantification of somatic alterations in plasma-derived, circulating tumor DNA (ctDNA) is gaining traction as a non-invasive and cost effective method of disease monitoring in cancer patients, particularly to evaluate response to treatment and monitor for disease recurrence. To our knowledge, genetic analysis of ctDNA in osteosarcoma has not yet been studied. To determine whether somatic alterations can be detected in ctDNA and perhaps applied to patient management in this disease, we collected germline, tumor, and serial plasma samples from pediatric, adolescent, and young adult patients with osteosarcoma and used targeted Next Generation Sequencing (NGS) to identify somatic single nucleotide variants (SNV), insertions and deletions (INDELS), and structural variants (SV) in 7 genes commonly mutated in osteosarcoma. We demonstrate that patient-specific somatic alterations identified through comparison of tumor-germline pairs can be detected and quantified in cell-free DNA of osteosarcoma patients.

KW - Circulating tumor DNA

KW - Next Generation Sequencing

KW - Osteosarcoma

KW - Targeted sequencing

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85042565317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042565317&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24268

DO - 10.18632/oncotarget.24268

M3 - Article

AN - SCOPUS:85042565317

VL - 9

SP - 12695

EP - 12704

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -